Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWRX5003
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Peptides
- Administration
- Transdermal
01
Overview
DWRX5003 is a microneedle patch formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being developed by Daewoong Pharmaceutical. It is designed for the treatment of obesity and type 2 diabetes mellitus. The microneedle technology aims to provide a minimally invasive, painless alternative to traditional subcutaneous injections, potentially improving patient compliance. By activating GLP-1 receptors, semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying, which collectively lead to improved glycemic control and weight loss. DWRX5003 is currently in Phase 1 clinical development to assess its safety and bioavailability compared to other semaglutide formulations.
- Other names
- semaglutide microneedle patch
02
Targets
Beyond the preview
Go deeper on DWRX5003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWRX5003.